Research location
Pelham
Alabama, United States
Advertisement
Research activity in Pelham
Alabama, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Pelham
16 linked trials · page 1 of 1A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation
RECRUITING
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979 · 2026-08-04 · 1 site observation
RECRUITING
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · 2026-05-21 · 1 site observation
RECRUITING
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 · 2026-05-11 · 1 site observation
RECRUITING
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · 2026-06-22 · 1 site observation
WITHDRAWN
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · 2024-11-05 · 1 site observation
COMPLETED
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · 2024-09-13 · 1 site observation
COMPLETED
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · 2023-09-27 · 1 site observation
COMPLETED
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06047548 · 2023-09-20 · 1 site observation
COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 2023-06-05 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related ComorbiditiesNCT05822830 · 2023-04-21 · 1 site observation
COMPLETED
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureNCT04714320 · 2021-04-28 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight LossNCT04660643 · 2021-03-29 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightNCT04184622 · 2019-12-04 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.